These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://tedxdqp835417.atualblog.com/45699096/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide